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Background: The appropriate criteria for patient selection are still a key issue in the clinical
management of patients referred to pulmonary rehabilitation (PR).
Methods: We retrospectively analyzed the records of a wide population of 1470 outpatient
or inpatients with chronic obstructive pulmonary disease (COPD) referred to standard PR at
two specialized Italian centers. Two models of multivariate logistic regression were devel-
oped to test the predictive powers of baseline exercise tolerance, namely the distance walked
in 6 mins (6MWD), and of baseline dyspnea on exertion, measured by the modified Medical
Research Council scale (mMRC), versus the minimal clinically important difference (MCID)
for the same outcomes.
Results: Compared to the category of individuals with 6MWD >350 meters, those patients
with 201–350 meters and ≤200 meters showed a higher probability (p<0.001) of predicting
a MCID change. Compared to the category of individuals with mMRC 0-1point, all the other
categories (2, 3, and 4) also showed a higher probability (p<0.001) of predicting a MCID
change. The incorporation of baseline categories of 6MWD and mMRC in a risk chart
showed that the percentage of patients reaching MCID in both variables increased as the
baseline level of 6MWD decreased and of mMRC increased.
Conclusion: This study demonstrates that lower levels of exercise tolerance and greater
perceived dyspnea on exertion predict achieving clinically meaningful changes for both these
treatment outcomes following PR. A specific risk chart that integrates these two variables
may help clinicians to select ideal candidates and best responders to PR.
Keywords: chronic obstructive pulmonary disease, pulmonary rehabilitation, patient
selection, minimal clinically important difference, exercise tolerance, dyspnea
Introduction
Pulmonary rehabilitation (PR) is a comprehensive and tailored intervention recom-
mended to patients with chronic obstructive pulmonary disease (COPD).1 In the
context of patient selection, PR provides benefits independently of baseline char-
acteristics and others such as age,2 functional stages,3 comorbidities,4,5 and physical
frailty.6 Even in cachectic COPD patients, a PR effect on physical capacity and on
muscle remodeling has been proven.7
Although, at least theoretically, all COPD patients are potential candidates to PR
based on the occurrence and persistence of symptoms and disability, it has been shown
that different multidimensional profiles,8 disability level at baseline,5 and dyspnea
perception may affect the response to PR and predict its likely effectiveness.9 Specific
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determinants of PR success concerning the degree of breath-
lessness, body weight, or gas exchange have been thus
identified.10 Walking limitation and perceived dyspnea, how-
ever, represent two common, easy-to-measure characteristics
of disabled COPD patients.1
In clinical practice around the world, themain factors that
impede the actual delivery of PR services to suitable
patients11 are related to limited funding and reimbursement,
lack of healthcare professionals and expertise,12 poor patient
awareness, and/or additional patient-related barriers.11 Since
PR is a challenging intervention for individuals and given the
current need to allocate the available resources properly,
referring clinicians should improve their ability to better
screen eligible patients. This would help to identify those
individuals that would benefit most from PR.
Accordingly, we investigated the predictive role of
both the baseline distance walked (6MWD) and the
mMRC (Modified Medical Research Council) Dyspnea
Scale score on successful PR, as defined by clinically
meaningful changes in these two relevant measurements.
Thus, in a population of COPD patients with different
categories of baseline disability referring to these two
outcome measures, we tested the probability of achieving
the minimal clinically important difference (MCID) for
both these patient-centered outcomes following PR.
Methods
Study Sample
This retrospective study analyzed stable COPD patients
admitted to a pulmonary rehabilitation program. The insti-
tutional review board and ethical committee of each hos-
pital approved the study, conducted according to the
Declaration of Helsinki. Patient data were treated confi-
dentially and patients' consent to review their medical
records was not required.
Patients were cared for by the Rehabilitation Unit of
Villa Pineta Hospital (Pavullo n/F (MO), Italy) from
2002 to 2010 (n=1394) or by the Respiratory Disease
and Lung Function Unit (Parma, Italy) from 2016 to
2018 (n=76). The primary diagnosis of COPD was
defined according to the Global Initiative for Chronic
Obstructive Lung Disease criteria.13 We excluded
COPD patients: a) with an acute event in the 4 weeks
prior to enrollment; b) with a coexisting diagnosis of
asthma or any other pulmonary disease; c) with any
comorbidity affecting exercise performance (anemia, dis-
abling neuromuscular conditions, acute cardiac failure,
malignancies); d) with cognitive impairments that might
have interfered with the adherence to the rehabilitation
program; e) who withdrew from the PR for any cause or
patients in whom it was not possible to obtain the mea-
sures of exercise tolerance or dyspnea perception at dis-
charge. Data on all patients were analyzed and reported
anonymously. No extramural funding was used to sup-
port the study.
General Measurements
Age, sex, and body mass index-BMI were recorded at
enrolment. Lung function was measured at baseline by
means of standard spirometry, performed according to
international recommendations.14 Arterial blood samples
were taken for gas analysis. Concomitant chronic diseases
were assessed by the self-reported Charlson Comorbidity
Index, which assigns to each disease a score that is pro-
portional to the related risk of death.15 The self-reported
prevalence of some chronic diseases (arterial hypertension,
diabetes, coronary disease, chronic heart failure, dyslipi-
demia, and osteoporosis) was collected.
Rehabilitation Program and Outcomes
Patients included were treated on an inpatient or outpatient
basis, depending on the individual’s level of functional lim-
itations, and the patient’s preference. The rehabilitation pro-
gram consisted of 21 consecutive 3 hr sessions and included
in each session standard activities (peripheral limb training,
respiratory muscle training, chest physiotherapy), and psy-
chological and nutritional counselling when indicated. The
program was conducted in the same way at the two facilities,
as previously reported.4 Physiotherapists involved were pre-
viously instructed to homogenize the type and duration of all
activities.4
The outcomes were analyzed as pre-to-post PR change in
exercise tolerance by the 6 min walking distance test
(6MWD) and perceived dyspnea on exertion by the modified
Medical Research Council Dyspnea Scale (mMRC). The
6MWD was performed according to the international
recommendations,16 and repeated twice to limit the leaning
effect; the best distance was recorded. The daily living activ-
ities-related dyspnea was evaluated with the Italian version
of the MRC modified by the American Thoracic Society.17
Statistical Analysis
Categorical variables are reported as number or percentage,
whereas continuous variables are indicated as medians
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(interquartile range) due to a non-normal distribution and are
then compared using the non-parametric Mann–Whitney
test.
Two models of multivariate logistic regression were
developed to test the predictive power of baseline 6MWD
and mMRC score versus the relative predefined post-PR
change (i.e. the minimal clinically important difference-
MCID) in both walking capacity (6MWD ≥30 meters)18
and dyspnea score (mMRC −1 point)19 (as the dependent
variables).
In the first model, we used baseline values of 6MWD
and mMRC as continuous variables. To explore the role of
these variables as outcomes, we retrieved the predicted
probability of reaching the MCID in both 6MWD and
mMRC for each patient from the final model and plotted
it against the respective absolute baseline values. In
the second model, we used categorical variables of base-
line 6MWD (≤200 meters, 201–350 meters, >350 meters)
and mMRC (0–1 points, 2 points, 3 points, 4 points). The
choice of these categories was based on the possibility of
distinguishing between patients with less impairment and
fewer symptoms (6MWD >350 meters and mMRC 0–1
points) and those who are more compromised (6MWD
≤200 meters and mMRC 4 points). The value limits of
the three 6MWD categories refer to the greatest, average,
or least performance20 and to the prognostic indication of
each in terms of mortality risk,21–23 as previously reported
in the literature. Both models were adjusted for age, sex,
comorbidities (Charlson index ≥ the median value of 2),
severity of airflow obstruction (forced expiratory volume
at 1st second – FEV1 ≤ 50% pred.), and clinical setting
(outpatient/inpatient). We then calculated the odds ratios
(ORs) and 95% confidence intervals (CI), and the calibra-
tion ability with the Hosmer-Lemeshow goodness-of-fit
test.
All analyses were performed using IBM SPSS, version
25.0 (IBM Corp., Armonk, NY, USA). A p-value of <0.05
was considered statistically significant.
Results
Our study cohort considered 1470 symptomatic COPD
patients who were elderly males with a moderate to severe
airflow obstruction, moderate number of comorbidities
(principally arterial hypertension), moderate walking abil-
ity and dyspnea perception. Data on body weight and gas
exchange were reported and then collected from a small
proportion of individuals (13% and 19%, respectively).
Chronic respiratory failure was present in 17% of the total
sample. General characteristics of our study sample are
reported in Table 1.
Figure 1 illustrates the linear regression analyses
exploring the predictive power of continuous baseline
6MWD and mMRC versus each respective MCID. The
risk of reaching the MCID increased for the 6MWD and
for the mMRC score in patients with a lower walking
capacity [odds ratio-OR 0.995 (95% confidence interval-
CI 0.993–0.998)] and a higher dyspnea level [OR 4.52
(95% CI 3.35–6.10)], respectively.
Figure 2 shows the significant distribution of pre-to-
post change in 6MWD (left panel) and mMRC (right
panel) according to the baseline categories. Patients with
a worse walking distance (6WMD ≤200 meters) and per-
ceived dyspnea (mMRC 3–4 points) had greater improve-
ment post-rehabilitation (p < 0.001 between each category
considered).
Table 2 reports the multivariate regression analyses
that explored the probability of achieving the MCID in
both 6MWD and mMRC, based on their baseline catego-
rical variables. Compared to the category of individuals
walking >350 meters, the categories of both those per-
forming 201–350 meters [OR 1.9 (95% CI 1.2–2.8)] and
those performing ≤200 meters [OR 1.5 (95% CI 0.86–2.8)]
Table 1 General Characteristics of Study Cohort (n=1470)
Variables n Value
Age, years 1463 71 [10]
Male, % 1470 75
BMI, kg/m2 185 26.7 [5.5]
FEV1, % pred. 1443 50 [23]
PaO2, mmHg 273 70 [12.9]
PaCO2, mmHg 274 40.9 [6.7]
Chronic respiratory failure, % 1470 17
Charlson index 1135 2 [1]
Hypertension, % 1277 30
Diabetes, % 1277 11
Coronary disease, % 1277 8
Chronic heart failure, % 1277 10
Dyslipidemia, % 1277 9
Osteoporosis, % 1277 5
6MWD, baseline 1467 360 [120]
mMRC, baseline 1174 2 [1]
SGRQ, baseline 569 40 [23]
Outpatients/Inpatients, % 1470 45/55
Notes: Data are shown as number of patients (%) or medians [interquartile range].
Percentages are calculated on non-missing data.
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume at 1
st
second; PaO2, partial arterial oxygen pressure; PaCO2, partial arterial carbon
dioxide pressure; 6MWD, six-minute walking distance; mMRC, modified Medical
Research Council Dyspnea Scale; SGRQ, St. George’s Respiratory Questionnaire.
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showed a higher probability of predicting the achievement
of the MCID for 6MWD, although the latter category was
not statistically significant (p=0.141). Similarly, compared
to the category of individuals with lower dyspnea on
exertion (0–1 point at mMRC), the other 3 categories,
representing progressively increasing levels of breathless-
ness, showed a higher probability of predicting the
achievement of the MCID for the mMRC.
The incorporation of baseline categories of 6MWD and
mMRC with the percentage of patients reaching the MCID
in both outcomes (6MWD ≥30 meters and mMRC −1
point) into a risk chart is reported in Figure 3. This chart
shows that few patients reached the MCID for both out-
comes (0–30%, red box) if they had higher baseline exer-
cise tolerance (6MWD >350 meters) and lower baseline
dyspnea perception (mMRC 0–1), while the percentage of
patients progressively increased (yellow and green boxes)
according to the increase in mMRC categories and the
decrease in baseline 6MWD.
Discussion
This retrospective study on a large cohort of COPD
patients admitted to a PR program provides two important
conclusions. First, it demonstrates that patients’ baseline
assessment in terms of both the distance walked (6MWD)
and their perceived dyspnea on exertion (mMRC) predicts
post-rehabilitation clinically meaningful changes. Second,
the risk chart integrating specific categories of these two
baseline measures identifies those patients who have
greater or lesser benefit from participating in PR, thus
Figure 1 Multivariate adjusted linear regression model predicting the probability of reaching the MCID in 6MWD and mMRC.
Figure 2 Distribution of pre-to-post PR changes in 6MWD and mMRC, according to the baseline categories.
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clarifying who is the best candidate in the selection of
patients.
To date, there is much evidence proving the efficacy of
a standard PR course in symptomatic COPD patients,1,18,24
even in those complex individuals who were previously
excluded from programs due to their physical frailty,6 degree
of comorbidities,5 or cachexia.7 Therefore, we now know that
these complex patients2,3,5–7 should not be excluded a priori
from rehabilitation.
Predictors of improvement following PR might be seen
on admission and include either degree of breathlessness,
body weight, or gas exchange (i.e. arterial partial pressure
of oxygen);10 however, gains and benefits in patients trea-
ted with PR are not predictable by other usual measures
such as sleep quality, social behaviors, and so on.10
To the best of our knowledge, this study is the first to
adopt an aimed and pre-specified hypothesis to explore the
role of two relevant and easy-to-collect outcome variables
(6MWD and mMRC) as predictors of improvement up to
MCID following a standard PR course.
At baseline, it is very likely that both of these two outcome
measures describe important characteristics of symptomatic
COPD candidates to PR.25,26 It is noteworthy that, a previous
prospective observational study of over 300 complex comor-
bid COPD patients5 showed the predictive role of baseline
6MWD and mMRC score on the efficacy of outpatient PR,
compared to other outcomes. Nevertheless, the present analy-
sis presents major differences compared to the study by
Crisafulli et al,5 namely 1) a stronger methodology to test the
hypothesis, with two regression models exploring continuous
and dichotomous variables of the outcomes considered (see
Figure 1 and Table 2); 2) a large study cohort including more
than 1400 candidates; 3) the assessment and analysis of
patients referred to either outpatient or inpatient PR settings; 4)
the adoption of updated criteria for the MCID in 6MWD (i.e.
+30 meters), different from that previously defined by
Redelmeier et al;27 5) a multiple adjustment of the regression
models,which considered several variables connoting patient’s
complexity and lung impairment, thus extending its validity to
the typical patients referred to a PR program in real life.
Our choice to categorize COPD patients by threshold
limits of 6MWD, although perhaps apparently arbitrary, was
in fact based on the previous literature20–23 and related to the
patients’ different performance and prognosis. As for the well-
known clinical and prognostic value of the different categories
of the mMRC17 that we also used in this study, we think that
the categories here proposed for the 6MWD represent different
levels of disability and might play a prognostic role similar to
that of mMRC in accurately predicting a meaningful gain
post-PR (Figure 2).
Table 2 Multivariate Regression Analyses Predicting the
Probability of Reaching the MCID in Exercise Tolerance and
Dyspnea Perception
Multivariate Adjusted*
OR 95% CI p-value
Dependent variable: MCID in
6MWD (≥30 meters)
Patients with baseline 6MWD
>350 meters (n=890)
1 – –
Patients with baseline 6MWD
between 201–350 meters (n=437)
1.9 1.2–2.8 0.003
Patients with baseline 6MWD
≤200 meters (n=140)
1.5 0.86–2.8 0.141
Dependent variable: MCID in
mMRC (−1 point)
Patients with baseline mMRC 0–1
points (n=230)
1 – –
Patients with baseline mMRC 2
points (n=412)
4.3 2.3–7.7 <0.001
Patients with baseline mMRC 3
points (n=320)
17.8 8.5–38.5 <0.001
Patients with baseline mMRC 4
points (n=212)
29.7 12.2–72.4 <0.001
Notes: *Adjusted for anthropometric characteristics, comorbidities, severity of
airflow obstruction, and setting. Hosmer-Lemeshow goodness-of-fit p=0.744 and
p=0.936 for models with dependent variable the MCID of 6MWD and mMRC,
respectively. Bold data indicate statistical significance.
Figure 3 Risk chart integrating baseline categories of exercise tolerance and of
dyspnea perception, with the percentage of patients reaching the MCID in both
outcomes (6MWD ≥30 meters and mMRC −1 point).
Abbreviation: NA, indicates not applicable.
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Since the response to PR may vary considerably among
COPD patients,10,28 as long as available resources are still
limited,11,12 it seems appropriate to implement a careful
selection process of all potential candidates once they are
referred to PR.1,11 Notwithstanding a global call to imple-
ment and expand the referral to PR worldwide,29 the selec-
tion process should inform the appropriate indication at the
individual level, something that remains a cornerstone in
this clinical field.
Our attempt to create an easy-to-interpret risk chart that
incorporates the measures of exercise tolerance and of
dyspnea perception on exertion (Figure 3) responds to
the actual need to identify the good responder to PR
(namely, the best candidate). Findings obtained with this
tool are in line with those reported very recently, which
show that different responses to PR in the COPD popula-
tion substantially depend on patients’ baseline profile, as
defined by a multidimensional assessment.8 In our study,
very good responders to PR were indeed those individuals
showing higher dyspnea and worse exercise tolerance at
baseline.8 Clearly, the identification of the best candidate
in our risk chart is based on these two outcomes.
Nonetheless, we cannot exclude that COPD patients may
also improve according to other outcome measures (i.e.
health status or health-related quality of life).1,10
Although COPD patients may show differential
responses to PR when considering different outcome
measures,19 the chance to incorporate multiple patient
domains into a single response to PR8 still remains con-
troversial and/or might be difficult to apply in different
contexts and organizations worldwide.30 Although the
approach of a cluster analysis based on the patient’s multi-
dimensional response to PR represents a novel and intri-
guing opportunity for clinicians,8 it does not substitute the
need for a very simple criterion for users. For example,
although cycle endurance time through a constant work-
rate test may predict response to PR in terms of exercise
tolerance, thus discriminating different categories of
response, skills and technologies might be not accessible
worldwide. In addition, there might also be other measures
that, at baseline, are not predictors per se.8 Therefore, in
future, global perspective to implementing PR and to
selecting ideal candidates, 6MWD and mMRC are still
identifiable as key outcomes.30 Indeed, our risk chart
starts from both the easy-to-use and the easy-to-interpret
concepts.
The strengths of this retrospective study are the large
cohort of patients included, the strong methodology based
on two different adjusted models of regression analysis,
and the original proposal of a chart to implement in the
selection process of candidates to PR. This latter might be
translated into a simple, practical message to help physi-
cians to prioritize resources, at least within the COPD
population.
Despite this, we here recognize some important limita-
tions that readers should also consider. First, the analysis
was based on retrospective data; our results need to be
confirmed prospectively. Second, we had limited access to
data on other outcomes (e.g. perceived health-related qual-
ity of life) as well as on other COPD-related factors such
as smoking status, long-term oxygen therapy, fat-free mass
index, physical activity level, and exacerbation rates,
which could not thus be integrated into the chart. Finally,
our analyses were done on a prevalence of males and
therefore need to be confirmed in a sample with more
females.
In conclusion, our study demonstrates that the baseline
levels of exercise tolerance and dyspnea on exertion, as
measured by two simple and accessible outcomes (6MWD
and mMRC) predict the COPD patient’s response to PR.
A risk chart incorporating these two variables may easily
identify any ideal candidate and best responder to
a standard PR course.
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